Publications of Patrizio Lancellotti
Coronary microvascular reserve and outcome in aortic stenosis: Pathophysiological significance vs. clinical relevance.
Lancellotti, Patrizio ; Nchimi Longang, Alain
in European Heart Journal (2017)Detailed reference viewed: 11 (0 ULg)
Le médicament du mois : Edoxaban (Lixiana (R)): nouvel anitcoagulant oral pour le traitement et la prévention secondaire des maladies thromboemboliques
SCHEEN, André ; LANCELLOTTI, Patrizio
in Revue Médicale de Liège (2016)Detailed reference viewed: 6 (0 ULg)
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent ; Lancellotti, Patrizio ; et al
in Endocrine (2016)
Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated ... [more ▼]
Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology. [less ▲]Detailed reference viewed: 14 (2 ULg)
Quantitative Three-Dimensional Color Flow Echocardiography of Chronic Mitral Regurgitation: New Methods, New Perspectives, New Challenges
; ; LANCELLOTTI, Patrizio
in Journal of the American Society of Echocardiography (2016), 29(10), 935-937Detailed reference viewed: 5 (0 ULg)
STRESS (EXERCISE) ECHOCARDIOGRAPHY in asymptomatic AORTIC STENOSIS
LANCELLOTTI, Patrizio ; DULGHERU, Raluca Elena
in ASE's comprehensive echocardiography, second edition (2016)Detailed reference viewed: 30 (3 ULg)
Malignant Mitral Valve Prolapse: Substrates to Ventricular Remodeling and Arrhythmias.
LANCELLOTTI, Patrizio ;
in Circulation: Cardiovascular Imaging (2016), 9(8), 005248Detailed reference viewed: 19 (3 ULg)
STRESS ECHOCARDIOGRAPHY FOR VALVE DISEASE/: AORTIC REGURGITATION AND MITRAL STENOSIS
LANCELLOTTI, Patrizio ;
in ASE's comprehensive echocardiography, second edition (2016)Detailed reference viewed: 18 (0 ULg)
Normal reference values for echocardiography: a call for comparison between ethnicities.
; LANCELLOTTI, Patrizio
in European Heart Journal - Cardiovascular Imaging (2016), 17(5), 523-4Detailed reference viewed: 21 (6 ULg)
Graphene coating onto mechanical heart valve prosthesis and resistance to flow dynamics.
LANCELLOTTI, Patrizio ; Oury, Cécile ; Jérôme, Christine et al
in Acta Cardiologica (2016), 71(3), 253-5Detailed reference viewed: 21 (3 ULg)
Predicting Reversibility of Anticancer Drugs-Related Cardiac Dysfunction: A New Piece to the Routine Use of Deformation Imaging.
Lancellotti, Patrizio ; ; Jerusalem, Guy
in Echocardiography (Mount Kisco, N.Y.) (2016), 33(4), 504-9Detailed reference viewed: 21 (2 ULg)
Targeting the tricuspid valve: A new therapeutic challenge.
LANCELLOTTI, Patrizio ; ; DULGHERU, Raluca Elena
in Archives of cardiovascular diseases (2016)Detailed reference viewed: 29 (8 ULg)
THE EACVI ECHOCARDIOGRAPHY TEXTBOOK - SECOND EDITION
LANCELLOTTI, Patrizio ; ; et al
Book published by Oxford University Press (2016)Detailed reference viewed: 6 (0 ULg)
Quantification of paravalvular regurgitation after transcatheter aortic valve implantation: improved accuracy means better standardization.
Lancellotti, Patrizio ; ;
in European Heart Journal - Cardiovascular Imaging (2016)Detailed reference viewed: 7 (0 ULg)
The clinical challenge of concomitant aortic and mitral valve stenosis.
; Lancellotti, Patrizio ;
in Acta Cardiologica (2016), 71(1), 3-6
The coexistence of mitral and aortic stenosis is not exceptional. Whereas rheumatic fever is currently plummeting in the Western countries, the incidence of degenerative disease is inversely increasing ... [more ▼]
The coexistence of mitral and aortic stenosis is not exceptional. Whereas rheumatic fever is currently plummeting in the Western countries, the incidence of degenerative disease is inversely increasing. The haemodynamic interactions which may interfere both with the usual echocardiographic parameters and with the invasive assessment may render the diagnosis difficult. The therapeutic challenges raised by this entity should not be underestimated. The increased morbidity and mortality of multivalvular surgery has to be balanced with the risk of a second operation down the line if one valvular involvement, deemed of a lesser importance, is neglected. This complex situation requires the multidisciplinary approach of a heart team involving surgeons, cardiologists, geriatrists if need be and imaging specialists. [less ▲]Detailed reference viewed: 12 (0 ULg)